AN2 Therapeutics, Inc.
ANTX
$0.03
Change (1 day)
$22.22
Year High
$0.87
Year Low
Categories
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
P/B ratio for AN2 Therapeutics, Inc. (ANTX)
P/B ratio as of 2023: 3.88
According to AN2 Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.88. At the end of 2022 the company had a P/B ratio of 1.94.
P/B ratio history for AN2 Therapeutics, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.88 |
| 2022 | 1.94 |
| 2021 | -6.09 |
| 2020 | -14.20 |
| 2019 | 59.96 |